Back to results
US 12,558,316 B2Granted
Methods and compositions for the treatment of epidermolysis bullosa
AssigneeUniversity of Miami
InventorEvangelos V. Badiavas
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating epidermolysis bullosa.
Claims16
A method of treating epidermolysis bullosa in a human subject in need thereof comprising:
- administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an enriched population of structurally and functionally intact heterogeneous population of vesicles collected from polyethylene glycol (PEG) precipitation from a biological fluid,
- wherein the heterogeneous population of vesicles are combined with a pharmaceutically acceptable carrier or excipient:
- wherein the isolated heterogeneous population of vesicles comprise a combination of exosomes and at least extracellular vesicles, ectosomes, microparticles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles;
- wherein the heterogeneous population of vesicles comprise one or more bioactive agents comprising RNA, DNA, lipid, carbohydrate, metabolite, peptide, protein and combinations thereof;
- wherein the biological fluid comprises mesenchymal stem cells;
- wherein the method of treating results in lower levels of inflammation and higher levels of tissue regeneration than a method of administering microvesicles isolated by ultracentrifugation;
- and
- wherein the method alleviates or reduces one or more symptoms of epidermolysis bullosa in the subject.
5 more elements
A method of treating dystrophic epidermolysis bullosa (DEB) in a human subject in need thereof comprising:
- administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a heterogeneous population of vesicles in order to alleviate or reduce one or more symptoms of DEB in the subject,
- wherein the heterogeneous population of vesicles are isolated by polyethylene glycol (PEG) precipitation from a biological fluid to obtain structurally and functionally intact isolated heterogeneous population of vesicles,
- wherein the isolated heterogeneous population of vesicles comprise a combination of exosomes and at least extracellular vesicles, ectosomes, microparticles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles;
- wherein the biological fluid comprises mesenchymal stem cells,
- wherein the isolated heterogeneous population of vesicles are combined with a pharmaceutically acceptable carrier or excipient.
2 more elements
A method of treating epidermolysis bullosa in a human subject in need thereof comprising:
- (a) administering a therapeutically effective amount of a pharmaceutical composition comprising structurally and functionally intact isolated heterogeneous population of vesicles comprising one or more bioactive agents to the subject;
- and
- (b) alleviating or reducing one or more symptoms of epidermolysis bullosa,
- wherein the heterogeneous population of vesicles have been isolated by polyethylene glycol (PEG) precipitation from a biological fluid to obtain structurally and functionally intact isolated heterogeneous population of vesicles that are combined with a pharmaceutically acceptable carrier or excipient to produce the pharmaceutical composition prior to administration to the subject,
- wherein the biological fluid comprises mesenchymal stem cells,
- wherein the pharmaceutical composition contains isolated heterogeneous population of vesicles ranging in size from 2 nm to 5000 nm,
- wherein the isolated heterogeneous population of vesicles comprise a combination of exosomes and at least extracellular vesicles, ectosomes, microparticles, nanovesicles, shedding vesicles, apoptotic bodies, and/or membrane particles,
- wherein the isolated heterogeneous population of vesicles are less inflammatory than those produced using ultracentrifugation,
- wherein the isolated heterogeneous population of vesicles are administered topically,
- wherein the structurally and functionally intact isolated heterogeneous population of vesicles comprise one or more bioactive agents comprising RNA, DNA, lipid, carbohydrate, metabolite, peptide, protein and combinations thereof, and
- wherein the method results in lower levels of inflammation and higher levels of tissue regeneration than a method of administering microvesicles isolated by ultracentrifugation.
8 more elements
Dependencies are inferred from the claim text.